US4963265A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Plasma processing device with anaphylatoxin remover
Assignee: Applied Immune Sciences Inc
•
Filing: 1988-05-06
•
Granted: 1990-10-16
•
Expires: 2008-05-06
Abstract
Abstract Blood derived fluids are subjected to modification resulting in the production of anaphylatoxins. The anaphylatoxins may then be removed by passing the modified blood through silicic acid particles in an amount sufficient to substantially reduce the anaphylatoxins, while still retaining the other blood components and without affecting adversely the use of the blood for the patient.
Inventors
- 👤 Thomas B. Okarma
- 👤 Brian R. Clark
- 👤 L. Bernard Lerch
- 👤 Chin-Hai Chang
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 00:50
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/12; A61K35/14; A61K35/16; A61M; A61M1/00; A61M1/36; A61M1/3679; Y; Y10; Y10S; Y10S210/00; Y10S210/902; Y10S210/908
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
53 words
A method for reducing elevated levels of anaphylatoxins in a blood derived fluid consisting of serum or plasma having an initial level of at least one of the anaphylatoxins at least two times greater than the original blood level of anaphylatoxins comprising: contacting said fluid with an anaphylatoxin reducing amount of silicic acid.
Claim 2
Independent Claim
53 words
A method for reducing elevated levels of anaphylatoxins in a blood derived fluid consisting of serum or plasma having an initial level of at least one of the anaphylatoxins at least two times greater than the original blood level of anaphylatoxins comprising: contacting said fluid with an anaphylatoxin reducing amount of silicic acid.
Claim 3
Dependent Claim
25 words
A method according to claim 1, wherein said silicic acid is present in an amount of from about 10 to 100 g/L of fluid treated.
Claim 4
Dependent Claim
59 words
A method according to claim 1, wherein said silicic acid is characterized by having a pH in the range of about 4 to 7, a size in the range of about 50 to 400 μ, a pore size in the range of about 50 to 350 Å, and a surface area of at least about 200 m 2 /g.
Claim 5
Independent Claim
109 words
A method for treating blood to be administered to a mammalian host, said method comprising: preparing plasma from said blood; selectively changing the composition of said plasma by contacting said plasma with a membrane which specifically affects the composition of said plasma, whereby the level of anaphylatoxins may be increased; and contacting said plasma with silicic acid characterized by being capable of substantially selectively removing proteins having molecular weights in the range of about 15 to 50 kD and having a pI of greater than about 7, said silicic acid present in an amount sufficient to reduce the anaphylotoxins to at least substantially the original level of said plasma.
Claim 6
Independent Claim
109 words
A method for treating blood to be administered to a mammalian host, said method comprising: preparing plasma from said blood; selectively changing the composition of said plasma by contacting said plasma with a membrane which specifically affects the composition of said plasma, whereby the level of anaphylatoxins may be increased; and contacting said plasma with silicic acid characterized by being capable of substantially selectively removing proteins having molecular weights in the range of about 15 to 50 kD and having a pI of greater than about 7, said silicic acid present in an amount sufficient to reduce the anaphylotoxins to at least substantially the original level of said plasma.
Claim 7
Dependent Claim
29 words
A method according to claim 4, wherein said membrane is an affinity membrane to which is covalently bonded a member of a specific binding pair homologous to said component.
Claim 8
Dependent Claim
15 words
A method according to claim 5, wherein said specific binding pair member is an antibody.
Claim 9
Independent Claim
120 words
A method for treating a person to change the level of a blood component, said method comprising: removing blood from said person and separating plasma from said blood; selectively removing at least one component of said plasma by contacting said plasma with a membrane which specifically modifies the concentration of said component, whereby the level of anaphylatoxins may be increased; and contacting said plasma with silicic acid characterized by substantially selectively removing proteins having a molecular weight in the range of about 15 to 50 kD and a pI of greater than about 7, said silicic acid present in an amount sufficient to reduce the anaphylatoxins to at least substantially the original level of said plasma in said first compartment.
Claim 10
Independent Claim
120 words
A method for treating a person to change the level of a blood component, said method comprising: removing blood from said person and separating plasma from said blood; selectively removing at least one component of said plasma by contacting said plasma with a membrane which specifically modifies the concentration of said component, whereby the level of anaphylatoxins may be increased; and contacting said plasma with silicic acid characterized by substantially selectively removing proteins having a molecular weight in the range of about 15 to 50 kD and a pI of greater than about 7, said silicic acid present in an amount sufficient to reduce the anaphylatoxins to at least substantially the original level of said plasma in said first compartment.
Claim 11
Dependent Claim
60 words
A method according to claim 7, wherein said silicic acid is characterized by having a pH in the range of about 4 to 7, pore size in the range of about 50 to 350 Å, an average particle size in the range of about 50 to 400 μ, and a surface area of at least about 200 m 2 /g.
References Cited (Backward Citations)
US3742946A
Cited
US4081431A
Cited
US4170590A
Cited
US3998946A
Cited
US4103685A
Cited
US4086924A
Cited
US4276172A
Cited
US4267047A
Cited
US4212738A
Cited
USRE31688E
Cited
US4610791A
Cited
US4272523A
Cited
US4223672A
Cited
US4428744A
Cited
US4464165A
Cited
US4362155A
Cited
US4512897A
Cited
US4540401A
Cited
US4627915A
Cited
US4614513A
Cited
US4693985A
Cited
US4814083A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-10-15 | 1994-04-16 | 1994-10-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-10-15 | 1998-04-16 | 1998-10-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-10-15 | 2002-04-16 | 2002-10-16 | $7700.00 | Window Closed / Lapsed |